# US 11,077,126 B2 · Use of carrimycin and pharmaceutically acceptable salts of carrimycin in manufacturing medicament for treating and/or preventing tumor

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 11,077,126 B2
- Document ID: US11077126B2
- Status: Granted
- Kind: B2
- Application number: 16/500,967
- Filed: 2018-04-05
- Published: 2020-01-30
- Granted: 2021-08-03
- Earliest claimed: 2017-04-06
- Assignees: Shenyang Fuyang Pharmaceutical Technology Co., Ltd.
- Applicants: Shenyang Fuyang Pharmaceutical Technology Co., Ltd.
- Inventors: Enhong Jiang; Mingyu Xia; Xunlei Jiang; Xundong Jiang
- Web page: https://patentgrep.com/patent/US11077126B2

## CPC

- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 35/04: specific for metastasis
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present disclosure provides use of carrimycin and pharmaceutically acceptable salts thereof for the preparation of a medicament for the treatment of tumors. The carrimycin and the pharmaceutically acceptable salts thereof have good curative effects on breast cancer, liver cancer, lung cancer, renal cancer, brain tumor, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric adenocarcinoma, colon cancer, lymphoma or leukemia and other tumors, and especially have obvious inhibitory effects on the growth of human breast cancer cells MCF-7 and MDA-MB-231, human hepatoma cells HepG2, human non-small cell lung cancer cells A549, human large cell lung cancer cells H460 and H1299, human renal clear cell adenocarcinoma cell 786-O, human renal cell adenocarcinoma cell 769-P, and human glioma cell U251.

## Claims

### Claim 1

A method for treating tumor, comprising administering a medicament comprising carrimycin or a pharmaceutically acceptable salt thereof to a subject,
wherein the tumor includes breast cancer, liver cancer, lung cancer, renal cancer, brain tumor, cervical cancer, prostate cancer, pancreatic cancer, esophageal cancer, gastric cancer, colon cancer, lymphoma or leukemia.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the medicament further comprises a pharmaceutically acceptable adjuvants.

### Claim 3 (depends on 1)

The method according to claim 1, wherein the medicament further comprises an anti-tumor drug and a pharmaceutically acceptable adjuvants.

### Claim 4 (depends on 1)

The method according to claim 1, wherein the medicament is a combination of a first agent and a second agent, the first agent contains carrimycin or the pharmaceutically acceptable salt thereof, and the second agent contains an anti-tumor drug.

### Claim 5 (depends on 3)

The method according to claim 3, wherein the anti-tumor drug is one or more selected from the group consisting of a chemotherapy drug, a radiotherapy drug, a targeted therapy drug, and an immunotherapeutic drug.

### Claim 6 (depends on 2)

The method according to claim 2, wherein a dose of the medicament is in a range from 5 to 1,500 mg.

### Claim 7 (depends on 4)

The method according to claim 4, wherein a dose of the first agent is in a range from 5 to 1,500 mg.

### Claim 8 (depends on 1)

The method according to claim 1, wherein the brain tumor is glioma or meningioma, and the gastric cancer is gastric adenocarcinoma.

### Claim 9 (depends on 4)

The method according to claim 4, wherein the anti-tumor drug is one or more than one drug selected from the group containing consisting of a chemotherapy drug, a radiotherapy drug, a targeted therapy drug, and an immunotherapeutic drug.

### Claim 10 (depends on 3)

The method according to claim 3, wherein a dose of the medicament is in a range from 5 to 1,500 mg.

### Claim 11 (depends on 6)

The method according to claim 6, wherein the dose of the medicament is in a range from 50 to 1,000 mg.

### Claim 12 (depends on 11)

The method according to claim 11, wherein the dose of the medicament is in a range from 100 to 400 mg.

### Claim 13 (depends on 7)

The method according to claim 7, wherein the dose of the first agent is in a range from 50 to 1,000 mg.

### Claim 14 (depends on 13)

The method according to claim 13, wherein the dose of the first agent is in a range from 100 to 400 mg.